1 week Ago By Defense World Staff
Geode Capital Management LLC reduced its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC.
The institutional investor owned 3,032,676 shares of the medical research company’s stock after selling 19,130 shares during the period. Geode Capital Management LLC owned about 2.36% of NeoGenomics worth $49,990,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in NEO. PNC Financial Services Group Inc. boosted its holdings in NeoGenomics by 5.
2% during the fourth quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 770 shares in the last quarter.
FMR LLC lifted its position in shares of NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after buying an additional 931 shares during the period.
Blue Trust Inc. lifted its position in shares of NeoGenomics by 33.2% during the 4th quarter.
Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock worth $73,000 after buying an additional 1,103 shares during the period. Versant Capital Management Inc grew its position in NeoGenomics by 174.
9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 1,142 shares during the period. Finally, SBI Securities Co.
Ltd. acquired a new position in NeoGenomics during the fourth quarter worth $26,000. Institutional investors own 98.
50% of the company’s stock. NeoGenomics Trading Up 4.7 %NEO stock opened at $9.
32 on Monday. The company has a quick ratio of 1.91, a current ratio of 1.
98 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc.
has a twelve month low of $8.05 and a twelve month high of $19.12.
The company has a market cap of $1.20 billion, a P/E ratio of -15.03 and a beta of 1.
41. The business has a fifty day moving average of $10.59 and a 200-day moving average of $13.
77. NeoGenomics (NASDAQ:NEO – Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.
02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05).
The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million.
NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%.
As a group, equities research analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.
Wall Street Analyst Weigh InNEO has been the topic of several recent analyst reports. Piper Sandler reduced their target price on shares of NeoGenomics from $21.00 to $18.
00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $19.00 to $18.
00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. The Goldman Sachs Group decreased their price target on NeoGenomics from $20.
00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, Bank of America cut their price objective on NeoGenomics from $19.
00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock.
According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.60.
View Our Latest Report on NEONeoGenomics Profile (Free Report)NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further ReadingFive stocks we like better than NeoGenomicsWhat Are Trending Stocks? Trending Stocks ExplainedIs McDonald’s Stock Serving a Value Meal to Investors? How Investors Can Find the Best Cheap Dividend StocksWalgreens Comeback? Private Equity Circling for a BuyoutInvesting In Preferred Stock vs. Common StockCoca-Cola Stock Looks Refreshing After the Relief Rally.
